Jonathan D. Macdonald

Jonathan D. Macdonald

Auto-generated profile, based on publicly available information

Jonathan D. Macdonald

Cleveland Clinic Center for Therapeutics Discovery (C3TD), Cleveland Clinic Research, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Cell Reports
Verified
Journal Article
Open access
EAErin R. Aho
Erin R. Aho
JWJing Wang
Jing Wang
RGRocco D. Gogliotti
Rocco D. Gogliotti
GHGregory C. Howard
Gregory C. Howard
JPJason Phan
Jason Phan
WTWilliam Tansey
William Tansey
The chromatin-associated protein WDR5 is a promising target for pharmacological inhibition in cancer. Drug discovery efforts center on the blockade of the "WIN site" of WDR5, a well-defined pocket that is amenable to small molecule inhibition. Various cancer contexts have been proposed to be targets for WIN site inhibitors, but a lack of understanding of WDR5 target genes and of the primary effects of WIN site inhibitors hampers their utility. Here, by the discovery of potent WIN site inhibitors, we demonstrate that the WIN site links WDR5 to chromatin at a small cohort of loci, including a specific subset of ribosome protein genes. WIN site inhibitors rapidly displace WDR5 from chromatin and decrease the expression of associated genes, causing translational inhibition, nucleolar stress, and p53 induction. Our studies define a mode by which WDR5 engages chromatin and forecast that WIN site blockade could have utility against multiple cancer types.

11 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FWFeng Wang
Feng Wang
KJKyu Ok Jeon
Kyu Ok Jeon
JSJames M. Salovich
James M. Salovich
JMJonathan D. Macdonald
Jonathan D. Macdonald
JAJoseph Alvarado
Joseph Alvarado
SFStephen W. Fesik
Stephen W. Fesik

30 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSSelena Chacón Simon
Selena Chacón Simon
FWFeng Wang
Feng Wang
LTLance R. Thomas
Lance R. Thomas
JPJason Phan
Jason Phan
BZBin Zhao
Bin Zhao
SFStephen W. Fesik
Stephen W. Fesik

14 November 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JMJonathan D. Macdonald
Jonathan D. Macdonald
SSSelena Chacón Simon
Selena Chacón Simon
Changho HanChangho Han
Changho Han
FWFeng Wang
Feng Wang
JSJ. Grace Shaw
J. Grace Shaw
SFStephen W. Fesik
Stephen W. Fesik

21 February 2013 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
JMJonathan Macdonald
Jonathan Macdonald
VOVictoria Oldfield
Victoria Oldfield
VBVassilios Bavetsias
Vassilios Bavetsias
JBJulian Blagg
Julian Blagg
We show that N3-MEM-protected imidazo[4,5-b]pyridines undergo efficient C2-functionalisation via direct C–H arylation. Twenty-two substituted imidazo[4,5-b]pyridines are prepared and iterative, selective elaboration of functionalised imidazo[4,5-b]pyridines gives 2,7- and 2,6-disubstituted derivatives in good yields from common intermediates. Mechanistic observations are consistent with a concerted-metallation-deprotonation mechanism facilitated by coordination of copper(I)iodide to the imidazo[4,5-b]pyridine.

6 October 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CRChitra Rawat
Chitra Rawat
SBSalma Ben-Salem
Salma Ben-Salem
NSNidhi Singh
Nidhi Singh
GCGaurav Chauhan
Gaurav Chauhan
ARAnja Rabljenovic
Anja Rabljenovic
HHHannelore Heemers
Hannelore Heemers
Prostate cancer remains the second leading cause of cancer death in men in Western cultures. A deeper understanding of the mechanisms by which prostate cancer cells divide to support tumor growth could help devise strategies to overcome treatment resistance and improve survival. Here, we identified that the mitotic AGC family protein kinase citron kinase (CIT) is a pivotal regulator of prostate cancer growth that mediates prostate cancer cell interphase progression. Increased CIT expression correlated with prostate cancer growth induction and aggressive prostate cancer progression, and CIT was overexpressed in prostate cancer compared with benign prostate tissue. CIT overexpression was controlled by an E2F2–Skp2–p27 signaling axis and conferred resistance to androgen-targeted treatment strategies. The effects of CIT relied entirely on its kinase activity. Conversely, CIT silencing inhibited the growth of cell lines and xenografts representing different stages of prostate cancer progression and treatment resistance but did not affect benign epithelial prostate cells or nonprostatic normal cells, indicating a potential therapeutic window for CIT inhibition. CIT kinase activity was identified as druggable and was potently inhibited by the multikinase inhibitor OTS-167, which decreased the proliferation of treatment-resistant prostate cancer cells and patient-derived organoids. Isolation of the in vivo CIT substrates identified proteins involved in diverse cellular functions ranging from proliferation to alternative splicing events that are enriched in treatment-resistant prostate cancer. These findings provide insights into the regulation of aggressive prostate cancer cell behavior by CIT and identify CIT as a functionally diverse and druggable driver of prostate cancer progression.Significance: The poorly characterized protein kinase citron kinase is a therapeutic target in prostate cancer that drives tumor growth by regulating diverse substrates, which control several hallmarks of aggressive prostate cancer progression.See related commentary by Mishra et al., p. 4008